The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes.
Chamorro. Clara I CI; Weber. Günther G; Grönberg. Alvar A; Pivarcsi. Andor A; Ståhle. Mona M
Key Findings
- LL‑37 reduces apoptosis in primary human keratinocytes and HaCaT cells exposed to camptothecin
- LL‑37 increases COX‑2 expression and boosts production of prostaglandin E‑2 (PGE‑2)
- LL‑37 raises levels of the anti‑apoptotic protein IAP‑2, and the protective effect is lost with a COX‑2 inhibitor
Practical Outcomes
- LL‑37 may be useful in topical formulas aimed at improving skin repair, wound healing, or managing psoriasis by limiting cell death. However, the research is limited to cell cultures, so optimal dosing, delivery method, and safety in humans are still unknown. Biohackers should view this as a promising concept that needs more in‑vivo validation before practical use.
Summary
The study found that the natural skin peptide LL‑37 can protect skin cells from dying when they’re stressed, by turning on a protective pathway involving COX‑2 and a protein called IAP‑2. This effect was seen in lab-grown human skin cells, not in people, and it was blocked when COX‑2 was inhibited.
Abstract
The human cathelicidin antimicrobial peptide LL-37 is involved in various aspects of skin biology, including protection against infection, wound healing, and also in psoriasis. The tight regulation of apoptosis is critical in tissue repair and its deregulation is a part of the psoriasis phenotype. Despite being involved in cell death of several cell types, virtually nothing is known about the function of LL-37 in keratinocyte apoptosis. Here we report that LL-37 peptide protects primary human keratinocytes and HaCaT cells from apoptosis induced by the topoisomerase I inhibitor camptothecin (CAM). In particular, pretreatment with LL-37 significantly decreased caspase-3 activity after CAM-treatment. Expression profiling of keratinocytes treated with LL-37 identified the upregulation of cyclooxygenase-2 (COX-2) expression, a gene implicated in protection from apoptosis. In addition to inducing COX-2 expression, LL-37 stimulated the production of its product, prostaglandin E-2 (PGE-2). Moreover, LL-37 induced the expression of inhibitor of apoptosis-2 (IAP-2), implicated in the COX-2/PGE-2 antiapoptotic pathway. Pretreatment with a selective COX-2 inhibitor abolished the antiapoptotic effect of LL-37 and reduced IAP-2 expression implicating that the antiapoptotic effect of LL-37 in keratinocytes is mediated by a COX-2-dependent mechanism involving IAP-2. Thus, overexpression of LL-37 may contribute to reduced keratinocyte apoptosis in conditions such as psoriasis.
Study Information
pubmed
2008
2008-10-16T00:00:00.000Z
10.1038/jid.2008.321
98
52